Skip to main content

Table 3 Multivariable Cox regression analysis of overall survival

From: Racial/ethnic differences in 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer

 

aHR

95% CI

P

Race

   

 Non-Hispanic White

Reference

  

 Hispanic White

0.85

0.77–0.94

0.001

 Black

1.1

1.02–1.19

0.01

 Asian/Pacific Islander

0.66

0.56–0.77

 < 0.001

Age

   

  < 50 years

Reference

  

 50 years or older

1.9

1.73–2.08

 < 0.001

Facility

   

 Nonacademic

Reference

  

 Academic

0.79

0.75–0.83

 < 0.001

Insurance

   

 None

Reference

  

 Private

0.62

0.51–0.76

 < 0.001

 Government

1.44

1.18–1.77

 < 0.001

Income

   

 Above median

Reference

  

 Below median

1.17

1.11–1.25

 < 0.001

Education

   

 Above median

Reference

  

 Below median

1.06

1.00–1.13

0.04

CDS

   

 0

Reference

  

 1

1.59

1.50–1.68

 < 0.001

 2 + 

2.72

2.51–2.95

 < 0.001

Year

   

 For every 1 year increase

1.02

1.01–1.03

0.002

Histology

   

 Ductal or lobular carcinoma

Reference

  

 Other

0.98

0.92–1.05

0.58

PR

   

 Positive

Reference

  

 Negative

1.09

1.02–1.16

0.02

T staging

   

 1

Reference

  

 2

1.49

1.42–1.57

 < 0.001

 3

2.26

1.95–2.63

 < 0.001

N staging

   

 0

Reference

  

 1a

1.61

1.52–1.71

 < 0.001

RS

   

 0–15

Reference

  

 16–25

1.16

1.10–1.22

 < 0.001

  ≥ 26

2.05

1.91–2.21

 < 0.001

Grade

   

 1

Reference

  

 2

1.14

1.08–1.21

 < 0.001

 3

1.5

1.39–1.61

 < 0.001

 Other

1.02

0.49–2.15

0.95

LVSI

   

 No

Reference

  

 Yes

1.15

1.08–1.23

 < 0.001

Chemotherapy

  

 No

Reference

  

 Yes

0.7

0.65–0.74

 < 0.001

Radiation

   

 No

Reference

  

 Yes

0.6

0.55–0.64

 < 0.001

Surgery

   

 Lumpectomy

Reference

  

 Mastectomy

0.73

0.67–0.79

 < 0.001

 Other

1.47

0.55–3.94

0.44

Margin

   

 Negative

Reference

  

 Positive

1.18

1.04–1.33

0.008

  1. aHR Adjusted hazards ratio, CI Confidence interval, CDS Charlson-Deyo Comoribidty Score, PR Progesterone receptor, RS 21-gene recurrence score, LVSI Lymphovascular invasion